Glenmark Pharmaceuticals announced that its subsidiary IGI received U.S. FDA Fast Track designation for ISB 2001, a treatment for relapsed/refractory multiple myeloma, on May 5, 2025. This designation aims to expedite the development and review of the drug, which has shown promising clinical results.